Introduction
Overweight patients with diabetes are encouraged to lose weight because fasting glucose levels and conventional cardiovascular risk factors improve. 1 However weight loss interventions produce less weight loss in patients with diabetes, than those without, for reasons that are unclear, 2 and similar changes have been previously reported for sibutramine. [3] [4] [5] Several therapies for type 2 diabetes, especially insulin and sulphonylurea use, induce weight gain. 6, 7 Therefore, the impact of different means of achieving weight loss in those with diabetes, and their effects on glucose metabolism and HbA 1c levels, merits further study. 8, 9 Although weight loss in general would be expected to improve health through its known effects on reducing cardiovascular risk factors (such as improvement in lipid levels and blood pressure), [10] [11] [12] [13] the Sibutramine Cardiovascular Outcomes study (SCOUT) found that in patients at high risk of cardiovascular disease cardiovascular morbidity (non-fatal stroke and non-fatal acute myocardial infarction) increased without increased mortality. [14] [15] [16] This was despite enhanced weight loss with the sibutramine therapy. These initial analyses did not investigate any potential effect of sibutramine on glucose metabolism and whether this might modify the overall cardiovascular risk profile. Sibutramine is a neurotransmitter reuptake inhibitor that reduces the reuptake of serotonin, norepinephrine, and dopamine and enhances satiety. [17] [18] [19] Sibutramine is associated with attenuation of the falls in blood pressure induced by weight loss and an absolute increase in heart rate, [14] [15] [16] these features normally being associated with sympathetic stimulation. Sibutramine is recognized to have a complex effect on the sympathetic nervous system with an adrenergic alpha type central blockade and a peripheral stimulation based on the inhibition of catecholamine reuptake. 20 Because stimulation of the sympathetic nervous system might be expected to increase blood glucose levels 21 we hypothesized that the sympathomimetic properties of sibutramine could influence glucose metabolism adversely and limit improvements in blood glucose and HbA 1c from weight loss.
Methods
SCOUT, a randomized, double-blinded, placebo controlled, and multicentre trial, was a cardiovascular outcome study of overweight and obese patients at increased risk for cardiovascular adverse events. Patient selection and outcome have been described in detail previously. 16 In brief, the inclusion criteria were subjects ! 55 years, body mass index (BMI) >27 kg/m 2 and 45 kg/m 2 , or a BMI! 25 kg/m 2 and < 27 kg/m 2 plus a waist circumference !102 cm if male and !88 cm if female. Furthermore, there was a requirement to have either documented atherosclerotic cardiovascular disease and/or type 2 diabetes with at least one of the following risk factors; hypertension, dyslipidaemia, current smoker, diabetic nephropathy, or both cardiovascular disease and diabetes. A history of coronary vascular disease included coronary artery disease, peripheral arterial occlusive disease, and stroke. The inclusion criteria were modified 15 months after the start of the enrolment due to a lower than expected event rate and required that the subsequent patients had diabetes together with pre-existing cardiovascular disease. The exclusion criteria were severe heart failure defined as greater than New York Heart Association functional class II, blood pressure > 160/ 100 mmHg, pulse rate > 100 beats/min, scheduled cardiac surgery/coronary angioplasty, or weight loss > 3 kg within 3 months prior to study baseline.
All patients underwent a single blinded, 6-week lead-in period in which all patients were given a 10 mg dose of sibutramine per day as well as advice on diet and exercise. They were then assigned in a random double-blinded manner to receive sibutramine 10 mg dose daily (longterm) or placebo in a randomly 1:1 ratio. Providing that they had no cardiovascular event or marked increases in blood pressure during the 6-week run-in period. Anthropometry (body weight, height) and a physical examination (including blood pressure, pulse), and samples for blood chemistry and haematology were obtained repeatedly throughout the study period. The individual treatment duration was defined as the time from randomization to the final visit. It is important to note that once patients were randomized, drug therapy was adjusted according to national guidelines, though the protocol required maintenance of the patient's normal drug and clinical management of diabetes, blood pressure, and blood lipids during the 6-week lead-in phase. If patients' blood pressure, lipids or fasting glucose levels did not conform to the goals set by national and international bodies, the SCOUT Executive Steering committee sent recurrent reminders to investigators to help ensure optimum management. Details of dose levels of the individual drugs were not recorded but the classes of drugs used were monitored to assess any major changes.
For the present analyses, blood samples from the initial screening visit and samples throughout the first 3 years of subsequently randomized patients were utilized. The blood biochemistry samples were taken while fasting but not at a standardized time of a day. Patients randomized to sibutramine or placebo were divided into four groups of weight change, over the first 2 years, classified as 'moderate' weight loss > 5.7 kg, 'modest' weight loss 3.7-5.7 kg, 'mild' weight loss < 3.7 kg, and weight gain-> 0 kg. Eighty per cent of the overall study population had type 2 diabetes with or without cardiovascular disease, and this analysis is confined to this subset of patients. The obese patients with type 2 diabetes mellitus included in this study were stratified by the addition of long-term sibutramine or placebo to the lifestyle modification intervention.
Ethics
All patients included in the SCOUT trial gave their written, informed consent before participating. The trial was approved by relevant ethical committees and was performed in the conformity with Declaration of Helsinki. The trial is registered at Clinical-Trial.gov number: NCT00234832.
Statistics
Analysis of variance and v 2 test were used to compare continuous and discrete variables. Linear regression models were used to examine the effect of multiple variables on changes in blood glucose concentrations. All calculations were made using SAS version 9.2 (SAS Institute, Cary, NC). The level of statistical significance was set at a P-value < 0.05.
Results
Of 9804 patients enrolled in the SCOUT study, 4898 continued on placebo and 4906 received sibutramine. In the placebo group 4079 had a diagnosis of type 2 diabetes, whereas in the long-term sibutramine group 4113 had type 2 diabetes. Body weights after 1st, 2nd, and 3rd year were available for 8319, 7283, and 6536 patients, respectively. Table 1 shows the baseline characteristics based on the four weight-change categories; initial weights were similar. Figure 1 shows the mean blood glucose and HbA 1c changes for each weight loss category in the two groups of patients (sibutramine and placebo), during the first 2 years. On average, weight loss was greater amongst those receiving sibutramine compared with those on placebo. For each weight loss category ( Table 2) , there was only a small fall in plasma glucose in the placebo group except in the highest (moderate) weight loss group. However, patients who received sibutramine and were in either the modest, mild weight loss or weight gain group showed a mean increase in blood glucose. HbA 1c changes showed a similar pattern. Table 2 presents these data in detail and also the results after 3 years. Changes in heart rate and systolic blood pressure are also presented and show that although blood pressure did fall in the sibutramine group it fell less than those on placebo in the same weight change categories. As with blood glucose and glycosylated haemoglobin there were consistently higher blood pressure values in the groups on sibutramine.
Adjusting for multiple variables, sibutramine administration was shown to increase blood glucose levels by 0.34 mmol/L and HbA1c-levels by 0.2%-units (P < 0.0001) ( Table 3) . Baseline weight, age, sex,
BMI, waist-hip ratio, diastolic blood pressure, low-density lipoprotein, high-density lipoprotein, beta-blockers, statins, diuretics, and other diabetes medications were not significantly associated with the selective changes in glucose associated with weight loss.
Discussion
This study confirms the effect of moderate weight loss achieved by diet and exercise results in reduced fasting blood glucose levels, but these changes were appreciably offset by sibutramine treatment. Changes in HbA 1c showed a similar pattern suggesting that sibutramine attenuated the impact of weight loss on overall glycaemic control.
These results are consistent with sympathetic stimulation by sibutramine increasing glycolysis and hepatic glucose production. Stimulation of adipose tissue lipolysis, a recognized sensitive responder to changes in sympathetic activity, would also increase free fatty acid flux thereby limiting tissue glucose uptake and oxidation through the effects of the Randle cycle. 22 Separate analyses did not show an expected relationship between an increase in heart rate and fasting glucose changes. Heart rate measures are very variable and were measured at only one time point in the 24 h cycle so an association may not have been detected. Therapeutic adjustments in medication also could theoretically have biased our findings; patients losing more weight may have been more likely to have their hypoglycaemic and/or hypotensive therapy reduced. If these therapeutic adjustments included reducing the dose of beta blocker or diuretic treatment (both of which may increase glucose levels), this would have tended to improve glycaemia. 23 The impact of such drug dose changes could not be assessed because although the classes of drugs used were monitored throughout the trial, detailed dose changes of individual drugs were not recorded.
Weight loss associated with the use of either placebo or sibutramine induced equivalent falls in cardiovascular mortality, 24 on glucose metabolism needs also to take account of the recognized negative effects relating to less blood pressure lowering and the positive effect of enhanced weight loss. Sibutramine treatment allowed more people to lose >5 kg (or 5%) weight than those given placebo; this level of weight loss is sufficient to reduce blood glucose, HbA 1c levels, and blood pressure, 20 which may have accounted for the overall benefit of reduced mortality and cardiovascular events by about a third in those who lost weight. 24 This would emphasize not only the importance of not giving sibutramine to patients with pre-existing cardiovascular disease but also amplifies the need to stop sibutramine treatment if adequate weight loss is not achieved, particularly in those with diabetes. Although sibutramine has been withdrawn from the market in several countries, this agent is available on prescription in some countries (e.g. Brazil) as well as being readily available (illegally) over the Internet. 26, 27 Moreover, various herbal weight-loss medicines available over the counter may contain sibutramine in high doses. 28 The observations of this study highlight the potential detrimental effects of sibutramine on blood glucose levels (in addition to its previously documented adverse impact on cardiovascular system, especially in those with pre-existing cardiovascular disease).
Implication
The withdrawal of sibutramine from the market in many countries holds important lesson for future development of treatment for obesity. Sympathomimetic weight-loss agents with similarities to sibutramine in their mode of action (e.g. phentermine) are currently still widely used to treat obesity. 29, 30 These agents increase heart rate and are not suitable for patients with a history of cardiovascular disease. 31 The result of our study clearly shows that the effects of pharmacological treatment of weight loss on blood pressure and glucose metabolism need to be carefully examined (also when using drugs with mechanisms of action similar to sibutramine). Thus, the benefits of weight loss may be substantially offset if the metabolic consequences of pharmacological treatment are different from those produced by weight loss induced by diet and exercise alone. 
Strengths and limitations of the study
The strengths of the study are that this study is based on a large, longterm randomized, double-blinded, placebo controlled, and multicentre cardiovascular outcome trial that makes the adjudicated data on primary outcome events robust. Some limitations of the study are that blood glucose levels in patients with diabetes can vary depending on the length of time with the disease, the type of therapy, changes in dosage, and the presence of different degrees of insulin resistance; however, the consistency of the data here does not suggest that these are important factors. There also may have been differences in the way diabetes was managed or therapy altered (dosage changes) but the data on dosage change (or lack of change) are not available.
Conclusion
A moderate weight loss achieved by diet and exercise reduces blood glucose and glycosylated haemoglobin in patients with diabetes. Similar weight loss obtained during sibutramine therapy was consistently associated with a lesser improvement in glucose metabolism. Studies evaluating other sympathomimetic weight-loss agents with modes of action similar to sibutramine are warranted.
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